534 Describing Peripancreatic Collections According to the 2013 Revised Atlanta Classification of Acute Pancreatitis: An International Interobserver Agreement Study Using the PANCODE System

G A A b st ra ct s on rifaximin. The cumulative incidence for EVB over five years was 10.9%, (4% on rifaximin compared to 16% not on rifaximin; P=0.004). Patients taking rifaximin had a lower hazard of first EVB then those not taking the medication (Figure 1). In multivariable analysis patients taking rifaximin had an 81% lower risk of bleeding within five years (HR 0.19 (0.06-0.57); P=0.003). There was no difference in survival between patients taking rifaximin and those not on the medication (P=0.18). Conclusion: The use of rifaximin in addition to standard medical therapy for the primary prophylaxis of EVB was associated with significantly reduced time to first EVB. This study potentially describes another use for rifaximin in decompensated cirrhosis, however, further prospective randomized control trial are necessary to validate the results.